Home › Funds › PenderFund Capital Management Ltd. › ESPR

PenderFund Capital Management Ltd. position in ESPR

ESPERION THERAPEUTICS INC NE

PenderFund Capital Management Ltd. reported holding 3,884,508 shares of ESPR (ESPERION THERAPEUTICS INC NE) in its Q2 2026 13F filing — a position valued at US$12.3M, representing 2.04% of its reported portfolio and ranking #16 among its reported holdings. PenderFund Capital Management Ltd. has disclosed ESPR holdings in 11 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)3.88M sh
Reported value held$12.28M
Portfolio Weight2.04%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How PenderFund Capital Management Ltd.'s ESPR position evolved

PenderFund Capital Management Ltd. first disclosed a stake in ESPR in Q3 2023 at 41,029,000 shares (US$29.8M). The position peaked in Q3 2024 at 40,429,000 shares, worth US$52.9M. Across 11 filings, PenderFund Capital Management Ltd. increased the stake 2 time(s), trimmed it 3 time(s) and left it unchanged 4 time(s). The most recent filing (Q2 2026) shows 3,884,508 shares valued at US$12.3M. Notable position changes include a 223% increase in Q2 2025, a 69% trim in Q3 2025, a 46% increase in Q4 2025.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 41.03M $29.83M New
Q4 2023 41.03M $32.54M Hold
Q1 2024 40.43M $46.69M Reduce
Q2 2024 40.43M $51.86M Hold
Q3 2024 40.43M $52.94M Hold
Q1 2025 3.00M $196.82K New
Q2 2025 9.68M $9.53M Add
Q3 2025 3.00M $3.04M Reduce
Q4 2025 4.39M $16.25M Add
Q1 2026 3.89M $10.66M Reduce
Q2 2026 3.88M $12.28M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ESPR and 13F data

ESPR (ESPERION THERAPEUTICS INC NE) is a company whose sector is not yet classified in our data. 40 other funds we track also report a position in ESPR — the largest reported positions include GLAZER CAPITAL, LLC (US$70.8M), ODDO BHF ASSET MANAGEMENT SAS (US$15.8M), Beryl Capital Management LLC (US$14.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ESPR

All ESPR fund holders →

FAQ

How long has PenderFund Capital Management Ltd. held ESPR?

PenderFund Capital Management Ltd. has disclosed ESPR holdings in 11 of the last 12 reported quarters, going back to Q3 2023.

What is PenderFund Capital Management Ltd.'s current position in ESPR?

As of Q2 2026, PenderFund Capital Management Ltd. holds 3.88M shares of ESPR (ESPERION THERAPEUTICS INC NE), valued at $12.28M, representing 2.04% of its reported portfolio and ranking #16.

Has PenderFund Capital Management Ltd. been buying or selling ESPR?

In the latest 13F filing (Q2 2026), PenderFund Capital Management Ltd. held unchanged its position in ESPR. The position peaked in Q3 2024 at 40.43M shares.

Which other funds hold ESPR?

Other major institutional holders of ESPR include GLAZER CAPITAL, LLC, ODDO BHF ASSET MANAGEMENT SAS, Beryl Capital Management LLC, among 40 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.